Company Monitoring Page for Regeneron

latest headlines for company on cafepharma

Sanofi and Regeneron solidify Dupixent TV ad lead, topping July pharma spenders again, trailed by AbbVie and Novo Nordisk
Fierce Pharma
Fri, 08/6/21 - 12:22 pm
Tags:
DTC advertising, television ads, Dupixent, Regeneron, Sanofi
Regeneron drug extends survival in lung cancer trial, lifting company's hopes in field
BioPharma Dive
Thu, 08/5/21 - 11:02 pm
Tags:
Regeneron, Sanofi, Libtayo, clinical trials, lung cancer
With expanded FDA nod, Regeneron's COVID-19 antibody drug can help the immunocompromised
Fierce Pharma
Mon, 08/2/21 - 10:56 am
Tags:
Regeneron, FDA, COVID-19, REGEN-COV
Lilly’s lebrikizumab looks to outdo Dupixent
EP Vantage
Mon, 08/2/21 - 10:48 am
Tags:
Eli Lilly, lebrikizumab, atopic dermatitis, Dupixent, Sanofi, Regeneron
New Drug Proves to Ease the Itch for Chronic Spontaneous Urticaria
BioSpace
Sat, 07/31/21 - 10:18 pm
Tags:
Regeneron, Sanofi, Dupixent, clinical trials, chronic spontaneous urticaria
FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings
Yahoo/Reuters
Sat, 07/31/21 - 10:11 pm
Tags:
Regeneron, FDA, COVID-19, Emergency Use Authorization, antibodies
AstraZeneca teams up with Regeneron for obesity-busting drug pact focused on genetics
Fierce Biotech
Tue, 07/27/21 - 10:29 am
Tags:
AstraZeneca, GPR75, obesity, Regeneron
Regeneron Plans to Create 1,000 New Jobs with $1.8 Billion Expansion in New York
BioSpace
Mon, 07/19/21 - 10:44 am
Tags:
Regeneron, New York, hirings
Regeneron plans $1.8bn investment to expand research facilities in New York, US
Pharmaceutical Business Review
Fri, 07/16/21 - 10:39 am
Tags:
Regeneron, New York, R&D
The top 15 blockbuster patent expirations coming this decade
Fierce Pharma
Mon, 07/12/21 - 11:05 am
Tags:
patents, patent cliff, AbbVie, Humira, Merck, Keytruda, Bristol Myers Squibb, Revlimid, Pfizer, Eliquis, Regeneron, Eylea, JNJ, Stelara, Opdivo, GSK, Dolutegravir, Ibrance, Januvia, Eli Lilly, Trulicity, Novo Nordisk, Victoza, Amgen, Prolia, Xgeva, Novartis, Cosentyx, Takeda, Entyvio
Regeneron pinpoints gene variants that protect against obesity, launches search for new drugs
Fierce Biotech
Thu, 07/1/21 - 10:38 pm
Tags:
Regeneron, genetics, obesity
Amgen dealt another blow in closely watched PCSK9 patent case against Sanofi, Regeneron
Fierce Pharma
Tue, 06/22/21 - 11:56 am
Tags:
Amgen, PCSK9 inhibitors, Sanofi, Regeneron, patents, Repatha
Sanofi and Regeneron's high-flying Dupixent tops May pharma TV spending, trading places with AbbVie's Humira
Fierce Pharma
Thu, 06/17/21 - 12:12 pm
Tags:
Sanofi, Regeneron, Dupixent, DTC ads, television ads
Regeneron antibody saves lives in some hospitalized Covid patients, study finds
Stat
Wed, 06/16/21 - 11:40 am
Tags:
monoclonal antibodies, Regeneron, COVID-19, UK
Regeneron shareholders urged to boot board member over executive pay practices
Stat
Tue, 06/8/21 - 09:48 pm
Tags:
Regeneron, executive pay, Leonard Schleifer
FDA authorizes Regeneron’s Covid drug at lower dose, and in injectable formulation
MedCity News
Sun, 06/6/21 - 10:36 pm
Tags:
Regeneron, FDA, COVID-19, Emergency Use Authorization
Regeneron resumes enrollment in lymphoma drug trials
Reuters
Mon, 05/17/21 - 11:05 pm
Tags:
Regeneron, clinical trials, FDA, lymphoma, odronextamab
Regeneron's Evkeeza shows promise in curbing high triglycerides, but will genetic disparities limit use?
Endpoints
Sun, 05/16/21 - 11:30 pm
Tags:
Regeneron, Evkeeza, high triclycerides, ACC
Pfizer, Regeneron CEOs see extended need for COVID-19 vaccines, treatments as pandemic enters next phase
Fierce Pharma
Tue, 05/11/21 - 10:09 pm
Tags:
Pfizer, Regeneron, pandemic, COVID-19, vaccines, Pharma CEOs, Albert Bourla, Len Schleifer
Regeneron’s golden goose Eylea may stave off biosimilar competition until 2024 or beyond
Endpoints
Tue, 05/4/21 - 10:39 am
Tags:
Regeneron, Eylea, biosimilars, macular degeneration

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.